UPM-Kymmene Oyj

UPM‑Kymmene and Andritz team up to fast‑track high‑value tissue innovation, cutting costs, shortening time‑to‑market, and boosting sustainability for SMEs.

UPM‑Kymmene pauses two pulp mills to cut costs, protect margins and focus on high‑margin products amid rising energy, carbon and supply‑chain pressures.

UPM‑Kymmene’s analyst resurgence: divestiture, cost cuts, & sustainable packaging boost—yet EU CBAM, commodity risks, and capital limits loom.

UPM‑Kymmene launches UPM PharmaSure, Vetro, and Endurance, high‑performance adhesives that keep labels bonded through sterilisation, cold‑chain, humidity, and chemical stress—boosting compliance, durability, and sustainability in pharma, spirits, an…

UPM‑Kymmene’s Q1 2026 earnings call highlights record renewable‑energy earnings and a strategic push into renewable fibre, advanced materials, and decarbonisation, underscoring governance excellence and growth amid market volatility.

UPM‑Kymmene’s steady cash flow, high dividend yield, and fast‑growing biochemicals arm it against paper‑cycle volatility, yet commodity‑driven valuation still limits upside.

UPM‑Kymmene’s €0.75 dividend triggered futures price tweaks, yet shares fell only 3 % amid a rally in European basic‑resources stocks—highlighting how corporate actions and macro drivers shape forest‑material market dynamics.

UPM‑Kymmene’s 2025 Q4 outlook: modest EPS turnaround, rising bioproduct revenue and AI‑driven cost cuts amid EU green rules—investors weigh growth vs. raw‑material risk.

UPM‑Kymmene’s upcoming 2025 earnings reveal modest EPS growth amid declining revenue, highlighting regulatory challenges, competitive gaps and circular‑economy opportunities.

UPM‑Kymmene gains institutional interest and UBS raises its target to €28, highlighting its strong fundamentals, sustainability focus, and growth potential in the forest‑products sector.